X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse GSK Pharma with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GSK PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
ADCOCK INGRAM
Jun-14
GSK PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs3,838379-   
Low Rs2,637274-   
Sales per share (Unadj.) Rs354.2112.8-  
Earnings per share (Unadj.) Rs39.8-28.4-  
Cash flow per share (Unadj.) Rs42.9-23.6-  
Dividends per share (Unadj.) Rs30.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs236.988.5-  
Shares outstanding (eoy) m84.70168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.12.9 315.9%   
Avg P/E ratio x81.4-11.5 -709.1%  
P/CF ratio (eoy) x75.5-13.9 -545.0%  
Price / Book Value ratio x13.73.7 370.7%  
Dividend payout %75.40-   
Avg Mkt Cap Rs m274,21655,082 497.8%   
No. of employees `0004.74.3 109.4%   
Total wages/salary Rs m4,8303,457 139.7%   
Avg. sales/employee Rs Th6,387.04,434.5 144.0%   
Avg. wages/employee Rs Th1,028.3805.3 127.7%   
Avg. net profit/employee Rs Th717.1-1,117.4 -64.2%   
INCOME DATA
Net Sales Rs m30,00019,037 157.6%  
Other income Rs m728133 546.2%   
Total revenues Rs m30,72819,171 160.3%   
Gross profit Rs m4,190-3,299 -127.0%  
Depreciation Rs m263822 32.0%   
Interest Rs m0516 0.0%   
Profit before tax Rs m4,655-4,503 -103.4%   
Minority Interest Rs m0-13 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m4570-   
Tax Rs m1,744281 619.8%   
Profit after tax Rs m3,368-4,797 -70.2%  
Gross profit margin %14.0-17.3 -80.6%  
Effective tax rate %37.5-6.2 -599.6%   
Net profit margin %11.2-25.2 -44.6%  
BALANCE SHEET DATA
Current assets Rs m16,74213,943 120.1%   
Current liabilities Rs m7,2027,845 91.8%   
Net working cap to sales %31.832.0 99.3%  
Current ratio x2.31.8 130.8%  
Inventory Days Days52111 46.7%  
Debtors Days Days21124 16.8%  
Net fixed assets Rs m8,6358,127 106.2%   
Share capital Rs m84788 958.3%   
"Free" reserves Rs m19,2220-   
Net worth Rs m20,06914,942 134.3%   
Long term debt Rs m105,251 0.2%   
Total assets Rs m30,03828,227 106.4%  
Interest coverage xNM-7.7-  
Debt to equity ratio x00.4 0.1%  
Sales to assets ratio x1.00.7 148.1%   
Return on assets %11.2-15.2 -73.9%  
Return on equity %16.8-32.1 -52.3%  
Return on capital %25.5-19.8 -128.5%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-6,6650-   
CASH FLOW
From Operations Rs m2,3601,625 145.2%  
From Investments Rs m3,008-499 -602.9%  
From Financial Activity Rs m-5,1084,766 -107.2%  
Net Cashflow Rs m2605,892 4.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.23 Rs / ZAR

Compare GSK PHARMA With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare GSK PHARMA With: ALKEM LABORATORIES  TTK HEALTHCARE  STRIDES SHASUN LTD  WYETH LTD  CADILA HEALTHCARE  



Today's Market

Sensex, Nifty at Record Close Yet Again; IT & Realty Stocks Rally(Closing)

Indian share markets extended rally in the final hour of the trade, hitting fresh record highs while the Bank nifty touched 27,000 level for the first time. At the closing bell.

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Jan 22, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - VENUS REMEDIES COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS